

European League Against Rheumatism (EULAR)

June 10–13, 2009

Bella Centre, Copenhagen, Denmark

Thursday 11 June 2009

Oral session

	Abstract No.	Abstract title	Authors	Time, Location & Session
R	OP-0022	Inhibition of joint damage and improved clinical outcomes with a combination of Rituximab (RTX) and methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) who are naive to RTX: a randomised active comparator placebo-controlled trial (IMAGE)	P. P. Tak, W. Rigby, A. Rubbert, C. Peterfy, R. F. van Vollenhoven, W. Stohl, E. Hessey, A. Chen, H. Tyrrell, T. Shaw	10.15-11.45 Auditorium 1 Session: New aspects of B cell depletion for RA
R	OP-0023	Immunization responses in rheumatoid arthritis patients treated with Rituximab results from a controlled clinical trial (SIERRA)	C. O. Bingham III, R. J. Looney, A. Deodhar, N. A. Halsey, M. Greenwald, C. Coddling, B. L.Trzaskoma, A. Kelman	10.15-11.45 Auditorium 1 Session: New aspects of B cell depletion for RA
R	OP-0025	Effectiveness and safety of Rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) or leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial	J. Wendler, HP. Tony, H. Soerensen, C. Richter, A.Krause, A. Rubbert-Roth, M. Bogdan, GR. Burmester	10.15-11.45 Auditorium 1 Session: New aspects of B cell depletion for RA
R	OP-0026	Long-term safety of Rituximab: follow-up of the RA clinical trials and re-treatment population	R. F. van Vollenhoven, P. Emery, C. O. Bingham III, E. Keystone, R. M. Fleischmann, D. E. Furst, K. M. Macey, M. T. Sweetser, A. Kelman, R. Rao	10.15-11.45 Auditorium 1 Session: New aspects of B cell depletion for RA

T	OP-0032	Lipid profile improves with the onset of Rheumatoid Arthritis (Mayo Clinic)	E. Myasoedova, H. Maradit Kremers, P. Fitz-Gibbon, C. S. Crowson, T. M. Therneau, S. E. Gabriel 10:15 - 11:45 Room C3 Session: Rheumatic diseases and cardiovascular comorbidity

General Poster session

11:45 – 1:30, Poster viewing area

	Abstract No.	Abstract title	Authors
T	THU0533	Is Fulfillment of ACR Response Criteria on Patients Receiving Tocilizumab Influenced by Its Profound Effects on the Acute Phase Response (APR)?	JS. Smolen, D. Aletaha, F. Alasti, D. Baker
T	THU0557	Physician Behavior in Response to Liver Enzyme Elevation in Rheumatoid Arthritis (RA) Patients on TNF Inhibitor (TNFI) and/or Methotrexate (MTX): Analysis of the CORRONA Registry Database	J. Kremer, G. Reed, A. K. John, A. Onofrei
T	THU0559	Application of the clinical disease activity index (CDAI) which does not comprise an acute phase reactant (APR) reveals the efficacy of tocilizumab irrespective of the inclusion of an APR for assessment of response	JS. Smolen, F. Alasti, D. Aletaha
T	THU0165	Improvement of ACR Core Set Components Among Tocilizumab-Treated Patients in DAS28 Remission: A Pooled Analysis of DMARD-IR Clinical Studies	E. C. Keystone, M. H. Schiff, J. Rovensky, M. Taylor, A. K. John, A. Balbir-Gurman

Friday 12 June 2009

Oral session

Abstract No.	Abstract title	Authors	Time, Location & Session
T OP-0157	Tocilizumab Inhibits Structural Joint Damage, Improves Physical Function, and Increases DAS28 Remission Rates in RA Patients Who Respond Inadequately to Methotrexate: The LITHE Study	J. Kremer, R. Fleischmann, J. Brzezicki, P. Ambs, E. Alecock, R. Burgos-Vargas, A. Halland	10:15-11:45 Hall A2 Session: Novel therapeutic approaches for RA
T OP-0158	Defining Remission in Patients Receiving Tocilizumab is Influenced by the Choice of the Composite Index Rather Than by Specific Effects on the Acute Phase Response	D. Aletaha, F. Alasti, JS. Smolen	10:15-11:45 Hall A2 Session: Novel therapeutic approaches for RA
T OP-0187	Gene Expression Profile In Peripheral Blood Cells At Baseline Predicts Tocilizumab Responsiveness Of Patients With Rheumatoid Arthritis	N. Nishimoto, Y. Kawata, C. Aoki, T. Mima	10:15-11:45 Auditorium 2 Session: RA - can we predict treatment response?

Poster session

11:45 – 1:30, Poster viewing area

Abstract No.	Abstract title	Authors
T FRI0239	The Efficacy And Safety Of Reinstitution Of Tocilizumab In Patients With Relapsed Active Rheumatoid Arthritis After Long-term Withdrawal Of Tocilizumab	A. Sagawa

T	FRI0252	Efficacy of Tocilizumab (TCZ) VS Methotrexate (MTX) Monotherapy in Patients with Rheumatoid Arthritis (RA) with No Prior MTX or DMARD Exposure	G. Jones, J. J. Gomez-Reino, M. B. Lowenstein, J. Tornero, A. Sebba, E. Alecock, E. Guarin, M. Genovese
T	FRI0262	Safety and Tolerability of Tocilizumab in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA) and Inadequate Response to MTX: 1-year results of the LITHE Study	J. Kremer, R. M. Fleischmann, D. Saurigny, E. Alecock, R. Blanco
T	FRI0133	Efficacy Of Tocilizumab (TCZ) In Rheumatoid Arthritis (RA): Interim Analysis Of Long-term Extension Trials Of Up To 2.5 Years	J. S. Smolen, R. H. E. Alten, J. Gomez-Reino, W. Rizzo, C. Davies, E. Alecock, R. van Vollenhoven
T	FRI0019	Over-produced IL-6 decreases blood lipid levels via up-regulation of VLDLR	M. Hashizume, H. Yoshida, N. Koike, M. Suzuki, M. Mihara
T	FRI0481	Increased Risk Of Gastrointestinal Events In Rheumatoid Arthritis	E. Myasoedova, N. J. Talley, C. S. Crowson, S. E. Gabriel
T	FRI0484	Prevalence Of Gastrointestinal Symptoms In Patients With Rheumatoid Arthritis: A Population-based Cross-sectional Survey	E. Myasoedova, N. J. Talley, N. J. Manek, C. S. Crowson, S. E. Gabriel
R	FRI0256	Autoantibody-positive rheumatoid arthritis (RA) patients (pts) have enhanced clinical response to rituximab (RTX) when compared with seronegative patients	JD Isaacs, E Olech, PP Tak, A Deodhar, E Keystone, P Emery, D Yocum, E Hessey, S Read
R	FRI0245	Long term treatment with Rituximab in rheumatoid arthritis: evidence for a learning curve by rheumatologists	A. Finckh, J. Dudler, C. Gabay, A. Scherer, L. Brulhart, D. Kyburz, A. Ciurea, D. Courvoisier
R	FRI0246	MabThera in rheumatoid arthritis (MIRA): results from a Belgian Rituximab registry	B. Vander Cruyssen, P. Durez, F. De Keyser, R. Westhovens
R	FRI0247	Rheumatoid arthritis treated with Rituximab in the real life: efficacy depend on rheumatoid factor positivity but not on methotrexate association or previous treatment with anti-TNF alpha	E. Solau-Gervais, JL. Legrand, E. Houvenagel, C. Prudhomme, P. Phillippe, RM. Flipo

Saturday 13 June 2009

Poster session

11:45 – 1:30, Poster viewing area

	Abstract No.	Abstract title	Authors
T	SAT0111	Long-Term Safety and Tolerability of Tocilizumab in Patients with a Mean Treatment Duration of 1.5 Years	R. van Vollenhoven, A. Rubbert-Roth, A. Cantagrel, D. Ridley, J. Dudler, D. P. Grimaldi, E. Alecock, J. Smolen
T	SAT0117	Normalisation In Serum Il-6 Levels Is A Good Biomarker For The Patients Who Can Cease The Corticosteroid Without Flare During Il-6 Receptor Inhibition Therapy With Tocilizumab	K. Terao, T. Tsuru, H. Nakoshima, M. Suzaki, N. Nishimoto, A. Atiyama
T	SAT0536	Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis	S.Yokota, T. Imagawa, T. Miyamae, T. kishi, U. Kaneko, N. Nishimoto, T. Kishimoto
T	SAT0081	Experience with Mycobacterium Tuberculosis Infection Reported in the Tocilizumab Worldwide RA Safety Database	R. F. van Vollenhoven, N. Nishimoto, H. Yamanaka, T. Woodworth, M. H. Schiff, A. Taylor, J. E. Pope
T	SAT0019	Relationships Between Changes in Biological Markers of Inflammation and Cartilage Metabolism and Radiological Progression in Patients with Rheumatoid Arthritis Treated with Tocilizumab Combined with Methotrexate: The LITHE Study	P. Garnero, E. Mareau, E. Thompson, N. Charni-Ben Tabassi, T. Woodworth, J. Kremer
R	SAT0121	Rituximab improved physical function and quality of life in patients with early rheumatoid arthritis: results from a randomized active comparator placebo-controlled trial of rituximab in combination with methotrexate compared to methotrexate alone in patients naive to methotrexate (IMAGE study)	W. F. Rigby, G. Ferraccioli, M. Greenwald, B. Montiel, R. Fleischmann, S. Wassenberg, A. Jahreis, L. Burke, C. Mela, A. Cher
R	SAT0097	Rate of serious infections in rituximab treated patients with rheumatoid arthritis that subsequently receive other biologic therapies	M. C. Genovese, F. C. Breedveld, P. Emery, S. B. Cohen, E. C. Keystone, E. L. Matteson, L. S. Burke, A. Chai, W. G. Reiss, M. T. Sweetser, T. M. Shaw
R	SAT0112	Rheumatoid factor predicts response to Rituximab in an European registry-based cohort: 6-month results from the collaborative European registries for Rituximab in rheumatoid arthritis (CERERRA)	K. Chatzidionysiou, R. van Vollenhoven, C. Gabay, M. Hetland, U. Tarp, J. Gomez-Reino, P. van Riel, K. Pavelka, D. Nordström, M. Tomsic, E. Lie, T. Kvien

Roche Symposium

Thursday 11 June 2009

	Title	Speakers	Time & Location
R	MabThera Satellite Symposium Charting the course: A pioneering vision for RA treatment	E Keystone (chair) A Rubbert-Roth R van Vollenhoven J Gomez-Reino P-P Tak J Isaacs	8:15-9:45 Bella Congress Centre Room A2
T	Actemra Satellite Symposium Breaking the barriers between clinical trials and clinical practice in RA – Transform living by distilling research findings	P-P Tak (chair) V Strand P Conaghan T Sokka	17:30-19:00 Bella Congress Centre Hall A1

Friday 12 June 2009

	Title	Speakers	Time & Location
O	Ocrelizumab Satellite Symposium Discovery and Innovation: Towards a new generation of treatment for autoimmune rheumatic diseases	D Isenberg (co-chair) C Kallenberg (co-chair) R Cervera D Jayne A Saraux	8:15-9:45 Bella Congress Centre Room C3

Roche Stand: C2-2, C2-3 & C2-4

R = rituximab (MabThera/ Rituxan)

T = tocilizumab (Actemra/ RoActemra)